πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

140 results for β€œcar-t” Clear

  1. CEA CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Gastric Cancer

    phase 1 mab active

    1 trial

  2. CEA CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Colorectal Cancer

    phase 1 mab active

    1 trial

  3. CEA-targeted CAR-T (Intravenous)

    Chongqing Precision Biotech Co., Ltd

    NSCLC (Advanced Non-small Cell Lung Cancer)

    phase 1 mab active

    1 trial

  4. CEA-targeted CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Lung Cancer

    phase 1 mab active

    1 trial

  5. CEA-targeted CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Peritoneal Metastases From Colorectal Cancer

    phase 1 mab active

    1 trial

  6. CEA-targeted CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Colorectal Cancer

    phase 1 mab active

    1 trial

  7. CLL1 and CD38 Dual-Target CAR-T Cell Injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial

  8. CNCT19 CAR-T cell therapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Autoimmune Hemolytic Anemia

    phase 1 mab active

    1 trial

  9. CY-219 CAR-T

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Relapsed/Refractory B-cell Lymphoma

    phase 1 small molecule active

    1 trial

  10. Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy

    Nanjing Legend Biotech Co.

    Lymphoma, B-Cell

    phase 1 small molecule terminated

    1 trial

  11. Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy

    Nanjing Legend Biotech Co.

    Refractory B Acute Lymphoblastic Leukemia

    phase 1 small molecule terminated

    1 trial

  12. Efficacy of LCAR-T2C CAR-T cells

    Nanjing Legend Biotech Co.

    T Cell Lymphoma

    phase 1 small molecule terminated

    1 trial

  13. Efficacy of LCAR-T2C CAR-T cells

    Nanjing Legend Biotech Co.

    CD4+ T Lymphocyte Tumor (T Cell Lymphoma and T Cell Leukemia)

    phase 1 small molecule terminated

    1 trial

  14. Fast Dual CAR-T Injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    B-cell Lymphoma

    phase 1 mab terminated

    1 trial

  15. GPC3 and/or TGFΞ² targeting CAR-T cells

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma

    phase 1 mab active

    1 trial

  16. GPC3-CAR-T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma

    phase 1 mab on hold

    1 trial

  17. GPRC5D CAR-T cell intravenous infusion

    The First People's Hospital of Lianyungang

    Plasma Cell Dyscrasias

    phase 1 mab active

    1 trial

  18. Intraperitoneal infusion of FAST CEA-targeted CAR-T

    Chongqing Precision Biotech Co., Ltd

    Colorectal Cancer

    phase 1 mab active

    2 trials

  19. Invivo CAR-T

    Chongqing Precision Biotech Co., Ltd

    B-Acute Lymphoblastic Leukemia

    phase 1 mab active

    1 trial

  20. KYV-101 anti-CD19 CAR-T cell therapy

    Kyverna Therapeutics

    Multiple Sclerosis

    phase 1 mab active

    1 trial

  21. LCAR-B4822M CAR-T Cell Immunotherapy

    Nanjing Legend Biotech Co.

    Refractory or Relapsed Multiple Myeloma

    phase 1 small molecule active

    1 trial

  22. LD and GC012F CAR-T Cell Injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Rheumatoid Arthritis

    phase 1 small molecule active

    1 trial

  23. LUCAR-20S CAR-T cells

    Nanjing Legend Biotech Co.

    Diffuse Large B Cell Lymphoma

    phase 1 small molecule terminated

    1 trial

  24. Metabolically Armed CD19 CAR-T cells

    Anhui Provincial Hospital

    Acute Lymphoblastic Leukemia

    phase 1 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources